Investment in follow-on biologics may benefit Insmed, Momenta

03/27/2008 | Bloomberg1

The investment of Momenta Pharmaceuticals, Insmed and Cell Therapeutics in technology to develop duplicates of biotech drugs may pay off if Congress allows the sale of follow-on biologics in the U.S. Momenta is working with Novartis AG's Sandoz unit to make a version of Lovenox, Sanofi-Aventis SA's blood thinner, and three other biotech medicines. Cell Therapeutics is working on a technology to simplify production of gene-based drugs, while Insmed will begin human trials of two follow-on biotech treatments this year.

View Full Article in:

Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Actuary
Meridian Health Plan
Detroit, MI
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Children's Health Plan
Houston, TX
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX